DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Orphan Drug Act of 1983
Orphan Drug Act of 1983
An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences
Regulatory and Ethical Issues for Orphan Medicines
Incentivizing the Utilization of Pharmacogenomics in Drug Development Valerie Gutmann Koch
The Orphan Drug Act
Orphan Drug Development: Incentives Under the Orphan Drug Act
Evaluatepharma® Orphan Drug Report 2017
Redesigning the Orphan Drug Act: Examining the Government’S Use of Subsidy and Exclusivity for Incentivizing Drug Development
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
Orphan Drug Utilization and Pricing Patterns (2012 - 2014) DATA BRIEF
Evaluatepharma® Orphan Drug Report 2015
Download Download
Food and Drug Administration Public Hearing
Alternative Drug Approval Pathways
An Overview of the Orphan Medicines Market in Turkey Güvenç Koçkaya, MD, Msc1,*, Albert I
2. Front Vellum
Orphan Drugs in the United States Exclusivity, Pricing and Treated Populations Introduction
Federal Register/Vol. 78, No. 184/Monday, September 23, 2013
An Analysis of the Morality of the Orphan Drug Act and Its Effects On
Top View
Orphan Drug Tax Credit on Treatments for Rare Diseases
Orphan Medical, Inc. (ORPH - $9.70) January 21, 2003 Initiating Coverage – Aggressive Growth STRONG BUY
How Drugs for Rare Diseases Became Lifeline for Companies Federal Law Gives Monopoly for Seven Years, Fueling Surge in Biotech Profits a Teen’S $360,000 Treatment
Evaluating the Need for an Orphan Drug Act in India by Comparing It with the US Orphan
Senza Titolo
Drug Regulation and Control
Small Market Drugs, Big Price Tags: Are Drug Companies Exploiting People with Rare Disease?
Policy Implications of the Orphan Drug Designation for Remdesivir To
The Orphan Drug Act: What's Right with It Gary A
The Orphan Drug Act Implementation and Impact
The Orphan Drug Act of 1983: a Case Study of Issue Framing and the Failure to Effect Policy Change from 1990-1994
Orphan Drug Report 2019
The Power of Patients
Rare Disease Landscape: Will the Blockbuster Model Be Replaced?
Patents and Regulatory Exclusivity
Rare Diseases and Orphan Products: Accelerating Research and Development
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
The Development of Orphan Drugs; a Financial and Ethical Decision
Extending Exclusivity for Biopharmaceuticals to Deter Competing Generics: a Review of Strategies, Potential Mitigation, and Similarities to Infringement
Orphan Drug Act
Orphan Drugs in the United States Providing Context for Use and Cost
The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development
Tension Between the Legal Intent and Social Purpose of the Orphan Drug Act
Jun 082011 Libraries Archives
Assessing the Effectiveness and Value of Drugs for Rare Conditions a Technical Brief for the ICER Orphan Drug Assessment & Pricing Summit